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The Australian Government has implemented new arrangements for public funding of vaccines over the
past 5 years. By utilising the standard Pharmaceutical Beneﬁts Advisory Committee (PBAC) application
process, whether for funding under the National Immunisation Program Schedule (NIP) or under theustralia
Pharmaceutical Beneﬁts Scheme (PBS), a predictable and transparent process for vaccine funding recom-
mendations has been established. This process uses the high-level technical resources available through
the Australian Technical Advisory Group on Immunisation (ATAGI) to ensure that both vaccinemanufac-
turers and the PBAC are optimally informed about all relevant aspects of population beneﬁts and delivery
of vaccines. ATAGI has a long-standing and mutually beneﬁcial dialogue with State and Territory Gov-
ernments, providers, and vaccine manufacturers to ensure that pipeline awareness, supply issues, and
all relevant scientiﬁc and clinical details are well understood.
. . Background
In the last 25 years, there has been a ‘second-wave’ explo-
ion in the availability of new vaccines resulting from protein
onjugates, acellular approaches, new molecular strategies and
djuvants. This bounty of safe and effective vaccines has created
he potential for substantial gains in the prevention, high-level
ontrol and even near-eradication of hitherto commonplace, life-
hreatening and disabling diseases. However, this potential cannot
e realized without effective funding mechanisms to provide free
r at least affordable vaccines to the population. Australia, with
population of about 22 million, is governed at three levels:
Commonwealth (or federal) Government; six state Govern-
ents (New SouthWales, Victoria, Queensland,Western Australia,
Abbreviations: ACT, Australian Capital Territory; ADEC, Australian Drug Eval-
ation Committee; ADRAC, Adverse Drug Reactions Advisory Committee; ATAGI,
ustralian Technical Advisory Group on Immunisation; AWP, ATAGIWorking Party;
DNA,CommunicableDiseasesNetworkAustralia; COAG,Council ofAustralianGov-
rnments; DoHA, Department of Health and Ageing; MAVIG, Medicines Australia
accine Industry Group; NCIRS, National Centre for Immunisation Research and
urveillance; NHMRC, National Health and Medical Research Council; NIC, National
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South Australia and Tasmania) and two major mainland territo-
ries (the Northern Territory and the Australian Capital Territory
[ACT]); and local governments at municipal level within these
states and territories. The national policy for public immunisa-
tion in Australia, the Immunise Australia Program, aims to increase
national immunisation rates by funding free vaccination programs,
administering the Australian Childhood Immunisation Register
and communicating information about immunisation to the gen-
eral public and health professionals. The policy takes account
of the shared responsibilities of the Commonwealth, States and
Territories and municipalities. The free vaccination programs are
listed under the National Immunisation Program (NIP) Schedule
(Fig. 1) (http://www.immunise.health.gov.au/internet/immunise/
publishing.nsf/Content/nips2). Funding for essential vaccines alone
was well in excess of $AU400m during the 2008–2009 ﬁnancial
year. The Commonwealth also provides funding to the States and
Territories to deliver immunisation programs in their respective
jurisdictions.
In the 1990s, recommendations for public funding of vaccines
for the Australian mass immunisation schedule came from an
expert sub-committee within the National Health and Medical
Research Council’s (NHMRC) advisory committee structure. This
sub-committee was responsible for the National Immunisation
Handbook (the Handbook)—the Government-produced national
Open access under CC BY-NC-ND licenseclinical guidelines aimed at all health professionals. These clini-
cal guidelines were not directly connected to Government vaccine
funding decisions. In 1997, the Government decided to bring this
advisory function inside the Department of Health and Ageing
(DoHA) and remove it from under NHMRC governance by creating
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nder the Minister for Health, with essentially the same functions
s the former NHMRC sub-committee. However, the provision of
dvice functionwas narrowed to provide conﬁdential advice to the
inister.
Fig. 1. The Australian National Imm(2010) A76–A83 A77
In 2005, the Government introduced legislation to bring vac-
cine fundingapplications into the sametransparentandpredictable
mechanism that had been used successfully for drugs. The Aus-
tralian Pharmaceutical Beneﬁts Scheme (PBS) has a long history
of acceptability to Government and to industry, with an effec-
unisation Program Schedule.
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sFig. 1.ive methodology to minimise price and to standardise a decision
ramework using cost-effectiveness evaluation based on a price per
isability- or quality-adjusted life year saved. These new arrange-
ents have produced a high quality policy framework that has
upported the introduction and public funding of many new vac-nued ).cines. Ultimately, however, aswith all countries, the capacity to pay
regardlessof futurehealth savings is an immediate issue forgovern-
ments that is constrained by the availability of funds drawn from
the public purse that must support the full range of government
commitments, both within and beyond the health sector.
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. ATAGI terms of reference, relationships and membership
.1. The terms of reference of ATAGI
The terms of reference of ATAGI are to:
provide technical advice to the Minister for Health and Ageing
on the medical administration of vaccines available in Australia,
including those on the NIP;
advise the Pharmaceutical Beneﬁts Advisory Committee (PBAC)
on matters relating to the ongoing strength of evidence pertain-
ing to existing, new and emerging vaccines in relation to their
effectiveness and use in Australian populations;
produce the Australian Immunisation Handbook for the approval
of the NHMRC;
consult with the National Immunisation Committee (NIC) on the
content and format of the Australian Immunisation Handbook
and implementation strategies; and
consult with the Communicable Diseases Network Australia
(CDNA), the Australian Drug Evaluation Committee (ADEC) and
the Adverse Drug Reactions Advisory Committee (ADRAC) on
matters relating to the implementation of immunisation policies,
procedures and vaccine safety.
.2. ATAGI and its relationship to other advisory bodies
There are a number of collaborating agencies that interact with
TAGI in the provision of advice and the formulation of policy and
unding decisions (Fig. 2). The National Centre for Immunisation
esearch and Surveillance (NCIRS) of vaccine-preventable diseases,
unded by the Australian Government, plays a major role in sup-
orting ATAGI and its working parties, described below. Formal
esponsibility for vaccine safetymonitoring resideswith theADRAC
f the Therapeutic Goods Administration. The PBAC plays a key
ole, describedbelow, inmakingvaccine funding recommendations
o Government, based on the manufacturer’s submission, ATAGI
dvice and other expert health economic inputs. The NIC chaired
y the Australian Government, is comprised of State and Territory
overnment immunisation directors plus members from themed-
cal and general practice community, NCIRS and consumers. Its role
s to coordinate a national approach to immunisation delivery and
o provide a forum for communication with the Commonwealth.
TAGI works closely with NIC to ensure that vaccine utilisation
dvice takes full account of program delivery matters. A number of
he committees listed in Fig. 2 have consumer representation.
.3. Relationship with the National Health and Medical Research
ouncil
The National Health and Medical Research Council (NHMRC)
s Australia’s principal body for supporting health and medical
esearch (http://www.nhmrc.gov.au/); for developing health
dvice for the Australian community, health professionals and
overnments (http://www.nhmrc.gov.au/guidelines/health
uidelines.htm); and for providing advice on ethical behaviour in
ealth care and in the conduct of health and medical research.
n relation to health advice, the NHMRC endorses and provides
uality assurance for a wide range of medical bodies’ recom-
endations, including ATAGI’s advice on immunisation and
he production of the Australian Immunisation Handbook (http://
ww.immunise.health.gov.au/internet/immunise/publishing.nsf/
ontent/Handbook-home). While ATAGI is responsible for pro-
uction of the Handbook, it must adhere to NHMRC guidance on
uideline development, including the use of levels of evidence
nd systematic reviews (http://www.nhmrc.gov.au/publications/
ynopses/cp30syn.htm). NHMRC is also bound byGovernment reg-(2010) A76–A83 A79
ulation to ensure that all its endorsed advice goes through a formal
process of public consultation and feedback. This process is man-
aged through the National Institute for Clinical Studies (NICS), an
agency of the NHMRC tasked with quality control and dissemina-
tion of clinical guidelines in Australia (http://www.nhmrc.gov.au/
nics/index.htm).
2.4. ATAGI membership
Members are appointed by the Minister of Health through an
informal nomination process for a term of 4 years, with the pos-
sibility of reappointment for 2 years or longer at the Minister’s
discretion. Membership is deﬁned by expertise in the following
categories: public health or practice nursing with expertise in vac-
cination procedures; general practice (private and pubic sector);
public health; expertise in the use of vaccines and immunobiologic
agents in clinical practice or preventive medicine; clinical or lab-
oratory vaccine research; expertise in the assessment of vaccine
efﬁcacy and safety; consumer expertise; adult infectious diseases;
or microbiology. One member is a member in common with the
PBAC. Ex ofﬁcio members include: Assistant Secretary, Immunisa-
tion Branch, (Ofﬁce for Health Protection) DoHA; Director, Drug
Safety and Evaluation, Therapeutic Goods Administration; repre-
sentative fromtheNIC; representative fromtheCDNA; andDirector
of the NCIRS of vaccine-preventable diseases.
2.5. Declaration of interests of ATAGI members
Members make formal annual written declarations of interest
to the Government. Prior to each meeting, a detailed agenda is
circulated to all members who identify up to date and current
potential conﬂicts of interest for each agenda item, providing detail
of the conﬂict. The Chair in consultation with the Government
ofﬁcers makes a determination as to whether themember can par-
ticipate in discussion on the item, contribute factual information
if required, remain in the room but silent, or be excluded from
the room for items where a potential for conﬂict exists. In gen-
eral, personal remuneration of other forms of direct or indirect
ﬁnancial or other beneﬁts for marketing or promotional activi-
ties are inconsistent with ATAGI membership. The decision points
around determinations of how declared conﬂicts will be managed
are not always absolute and may evolve over time. Regular discus-
sion between the chair of ATAGI and the chair of PBAC and with
members of Government is conducted to review speciﬁc issues as
they arise. Australia with a small population, has a limited pool
of highly expert individuals, and their involvement with industry
in clinical research is regarded positively. Therefore, involvement
in industry-sponsored vaccine research where payment is made
to an institution and not to the individual is generally not consid-
ered a conﬂict requiring exclusion, and a member may be involved
in discussion or provision of factual information. Conﬂicts may
involve the Chair and may require that the Chair vacate their posi-
tion for a speciﬁc discussion or decision on a recommendation
if judged by Government ofﬁcers to be required. ATAGI Work-
ing Party (AWP) members must also abide by these rules (see
below).
3. Process for new vaccine recommendations
The ATAGI provides technical advice on vaccines well before
licensure of a new vaccine (Fig. 3). Early and open communication
between the vaccine manufacturer and the Australian regulator
(Therapeutic Goods Administration) is essential, and severalmech-
anisms described below have been built into the process to ensure
that this occurs. The process for informing Government’s decision
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n whether or not to fund a new vaccine under the NIP or the PBS
roceeds in a number of phases.
.1. ATAGI scoping phase
A continuous process of ‘horizon scanning’ is conducted by
TAGI to forecast impending licensure of new vaccines. Formal
nteraction with vaccine manufacturers via an annual industry day
ontributes importantly to this, giving manufacturers an opportu-
ity to provide an ‘in-conﬁdence’ brieﬁng on their development,
rialling and registration submission plans. ATAGI establishes a
ub-committee, an AWP, far ahead of the anticipated time of a new
accine licensure and subsequent PBAC submission by the com-
any. A detailed and structured document is produced by the AWP
or ATAGI consideration. Following any necessary modiﬁcation, a
BACpre-submission advice is compiled based on an agreed frame-
ork developed jointly by ATAGI and the PBAC, and reﬂects the
ey points outlined in the Vaccine Appendix of the PBAC process.
his process considers issues related to the suitability of includ-
ng a new vaccine into the NIP including: implications for herd
mmunity (neither necessary nor sufﬁcient for a positive recom-
endation for NIP suitability); general or targeted immunisation;
eed for catch-up program; schedule issues (dosing, boosters,
t with existing NIP vaccines); alternatives to vaccine; clinicaltributing to vaccine policy and decision-making.
uncertainties and special considerations; requirements for imple-
mentation and likely consequences for other patterns of resource
provision related to the NIP; and any other relevant considerations
(http://www.health.gov.au/internet/main/publishing.nsf/Content/
AECB791C29482920CA25724400188EDB/$File/PBAC4.3.2
(01DEC08).pdf). In some speciﬁc circumstances, a possible
alternative to NIP listing is a co-funding arrangement (the patient/
consumer pays a subsidised proportion of the full cost) under the
PBS as applies to publically funded drugs that are prescription-
based.
3.2. PBAC phase
The ATAGI Pre-submission Advice is provided to both PBAC and
to the submitting company (known as the sponsor). This process
is designed to ensure that the vaccine manufacturer fully under-
stands the formal public health and technical considerations that
are material to the public interest, with the exception of cost-
effectiveness, which is the province of PBAC. Following submission
of a company’s application to the PBAC for NIP or PBS listing of a
vaccine, preliminary evaluation by the PBAC Secretariat with key
PBAC members may result in further questions to ATAGI regarding
a range ofmatters pertaining to the submission. This may include a
request toverify a claimmade in thedossier (for example, regarding
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n immunologic correlate of protection), or to clarify interpre-
ation of a speciﬁc piece of evidence. In response to a formally
ommunicated set of questions copied to the manufacturer, the
WP prepares a post-submission advice that is presented to ATAGI
or modiﬁcation if required and endorsement. This advice is then
ommunicated to the PBAC and copied to the manufacturer. Par-
llel to this, a detailed commentary on the sponsor’s submission is
repared for the PBACby a consultant under contract to theDepart-
ent of Health. The PBAC also has an Economic Sub-committee
ESC) that reviews and interprets the economic analyses in these
ubmissions and provides written advice. Both of these documents
re also copied to the manufacturer, which has an opportunity to
espond. Formal determination on the application is then made by
he PBAC. This process, its assumptions and economic principles
emains subject to some continuing debate and discussion [1–3],
ut is widely accepted by industry, and healthcare professionals..3. Post-submission phase
Funding decisions for vaccines are made by the Government.
f PBAC makes a positive recommendation the Government isunding of vaccines.
not obliged to fund a new vaccine, but the Government can-
not fund a vaccine without a positive recommendation from
PBAC. There is no time limit set for the Government to make its
funding decision. Price negotiation is handled by the Australian
Government’s Pharmaceutical Beneﬁts Pricing Authority (PBPA,
http://www.health.gov.au/internet/main/publishing.nsf/Content/
pbs-pbpa-policies-contents∼pbs-pbpa-policies-intro).
3.4. Development of recommendations and the basis for
decision-making
The ATAGI has a formal process for establishing AWPs including
speciﬁc terms of reference, an expected end point, and member-
ship. All AWPs are chaired by an ATAGI member, and depending
on the issue, may be co-chaired by the senior representative from
another statutory group such as CDNA or NIC, depending on the
issue. Membership is always expertise-based, and may involve
other ATAGI members, NIC members, and experts in a speciﬁc area
who are not members of ATAGI provided they are free of high-
level conﬂicts of interest. In this last case, where unique outside
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xpertise is required, an invitation to submit technical material or
ther advice may be sought, but they cannot be an active member
f the AWP. AWPs are supported by one or more scientiﬁc ofﬁcers
rom the NCIRS who are responsible for assembling the written
eport, obtaining resource materials and conducting further anal-
sis if required. Crucial to the quality and timely delivery of high
uality advice to Government and to providers is the policy branch
f the NCIRS. (http://www.ncirs.usyd.edu.au/).
.5. Role played by the Pharmaceutical Beneﬁts Advisory
ommittee (PBAC)
Since 2005, the vaccine funding advisory framework inAustralia
as changed to bring vaccines into the overall policy frame-
ork that has been used for drugs for some years. The PBAC was
stablished to consider submissions, usually from manufacturers,
ased on cost-effectiveness applications for pharmaceuticals or
ew vaccines. The Chair of the PBAC is appointed full-time, but the
ommittee’s membership is otherwise made up in a similar way
o that of the ATAGI, with clinicians, academics and others with
articular expertise. PBAC meets three times annually to consider
ubmissions, and then provides a recommendation to Government
n whether or not to fund and on what basis. In the case of vac-
ines, the sponsor may submit for either NIP listing (free to eligible
eople and listed on theNIP), or PBS listing (requires a co-payment,
nd is not listed on the NIP).
.6. Criteria for NIP listing
In Australia, the general criteria for suitability for listing on the
IP are deﬁned in the Vaccine Appendix of the PBAC submission
ramework (Table A.1).
. Role of industry, and other private and professional
nterest groups
Medicines Australia is the umbrella group representing phar-
aceutical manufacturers in Australia, and its sub-committee the
edicines Australia Vaccine Industry Group (MAVIG), is a consor-
ium of vaccine manufacturers. MAVIG has played an important
ole in coordinating the industry view of national policy matters
n industry’s representation to Government. It played a key role in
he consultation and development phase of the vaccine appendix
o the PBAC guidelines (Table A.1). ATAGI conducts formal ‘in cam-
ra’ consultations with vaccine manufacturers annually (ATAGI
ndustry Days) at which companies separately present their lat-
st developments and plans for vaccines. This has proved to be
n important two-way communication process to permit ATAGI
o plan its working party activities and to coordinate with PBAC
or pre-submission advice for upcoming submissions. The process
lso permits industry to canvas ATAGI views on public health and
ther relevant perspectives on their products, including scheduling
ssues, technical matters pertaining to assumptions or data inputs
o cost-effectiveness analyses, and many other matters.
The NHMRC-mandated requirement for full public consulta-
ion relating to clinical guidelines ensures complete and open(2010) A76–A83
access topotential recommendationsmadebyATAGI.Regular input
is received from the professional colleges and unions, consumer
groups, state and local government, clinicians and public health
workers. However, they do not actively participate in ATAGI dis-
cussions, and ATAGI does not conduct open forums.
5. Future developments
ATAGI produces highly detailed and structured AWP reports
for new vaccines that form the basis for PBAC submission advice
and the content of the Australian Immunisation Handbook. These
reports are informed by published and unpublished clinical trials
and other up to date evidence, some of which is submitted by the
vaccine manufacturer as outlined above. Because of restrictions on
releasing as yet unpublished clinical trial data, or other commer-
cial restrictions by the companies, unabridged AWP reports are not
made public. A process to reﬁne these reports to address these
restrictions to permit their public airing in a timely fashion is under
consideration.
The Australian Government will develop a new National
Immunisation Strategy in 2010. A process of wide stakeholder con-
sultation will precede the strategy development. A number of key
issues will be canvassed with stakeholders such as vaccine sup-
ply, efﬁcacy and quality, education and workforce development,
surveillance and research development, data systems, service
delivery, and governance arrangements.
In early 2008, the Council of Australian Governments (COAG)
representing all the State and Territory Governments of the Com-
monwealth, agreed to the direct purchasing of essential vaccines,
under the National Immunisation Program by the Commonwealth,
which commenced from 1 July 2009. The precise arrangements
to facilitate this new process will be based on the National
Partnership Agreement on Essential Vaccines that is available at
http://www.federalﬁnancialrelations.gov.au.
6. Conclusion
TheAustralian approach to vaccine policy development (includ-
ing vaccine funding decision-making) is a multi-part activity that
attempts to bridge federal and state roles and responsibilities with
high-quality scientiﬁc foundations embedded in a national health
funding model that is founded on equity of access for all. As the
cumulative price for publically funded vaccines climbs, compet-
itive pressure for access to the ﬁnancial investment required to
deliver the potential health service savings and health outcome
returnmust have a solid basis in clinical andpublic health evidence.
Trading off competing demands of commercial priorities, access to
population markets, transparency of process, and a level playing
ﬁeld are all elements to be built into this framework. Continued
improvement of all aspects of the model, including the way the
ATAGI functions, is essential to maintain relevance in the changing
global environment.Appendix A.
See Table A.1.
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Table A.1
Vaccine Appendix of the Pharmaceutical Beneﬁts Advisory Committee (Extracted from page 221 of http://www.health.gov.au/internet/main/publishing.nsf/Content/
AECB791C29482920CA25724400188EDB/$File/PBAC4.3.2(01DEC08).pdf.
Several factors affect whether vaccines will be listed on the PBS or be funded under the NIP. A vaccine should generally be proposed for
funding under the NIP where there is expected to be an additional health beneﬁt to the community beyond the individuals vaccinated,
which would be improved by maximising coverage rates of the proposed vaccine in the identiﬁed individuals. More speciﬁc
considerations favouring a submission for NIP funding include the following:
• The target for the proposed vaccine is a broader population in which there is either no need to assess risk factors for the disease in each
individual, or the assessment of risk factors at an individual level is straightforward (e.g. age, sex, ethnicity, geography).
• There is a reason to maximise population coverage of the proposed vaccine because the proposed vaccine reduces one or more of:
◦ the proportion of susceptible individuals
◦ carriage of the pathogen(s) affected by the vaccine
◦ transmission of the infection (including nosocomial infections or reducing the rate or extent of spread of infections in other
institutional settings, such as child care centres, schools or nursing homes).
◦ Integral to these speciﬁc considerations are as follows:
◦ The proposed vaccine protects against a new infection or reactivation of an existing infection.
◦ The efﬁcacy of the proposed vaccine is sufﬁcient to achieve one or more of the reductions identiﬁed in the second bullet point,
above (e.g. reductions in the proportion of susceptible individuals, carriage of the pathogen affected by the vaccine, or transmission of
the infection).
◦ The disease is sufﬁciently severe or prevalent in an unimmunised population to justify maximising the use of the proposed vaccine
in order to achieve its full community health beneﬁt.
◦ The proposed vaccine needs only to be delivered as a single dose or a few doses.
An additional factor that might be considered in supporting a request for funding under the NIP is the existence of claimed advantages of
increasing herd immunity, particularly where those advantages are supported by clinical evidence (see additional requests below in
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